Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation

Circulation Research

Volumn 102, Issue 8, 2008, Pages 933-941

  Chang, Po Yuan ^a   Lu, Shao Chun ^a   Lee, Chii Ming ^a   Chen, Yi Jie ^a   Dugan, Tracey A ^d   Huang, Wen Huei ^a   Chang, Shwu Fen ^b   Liao, Warren S L ^c   Chen, Chu Huang ^d   Lee, Yuan Teh ^a,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e NONE   (Taiwan)

Author keywords

DNA methylation; Endothelial cells; Growth factors; Homocysteine; Transcriptional regulation

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DEOXYCYTIDINE; FIBROBLAST GROWTH FACTOR 2; GUANINE NUCLEOTIDE BINDING PROTEIN; HOMOCYSTEINE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; PERTUSSIS TOXIN; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL SURVIVAL; CONCENTRATION RESPONSE; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MITOGENESIS; NICK END LABELING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ARTERIES; CATTLE; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GTP-BINDING PROTEINS; HOMOCYSTINE; TRANSCRIPTION, GENETIC;

EID: 42549135938     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.171082     Document Type: Article

References (48)

1. Schimke RN, McKusick VA, Huang T, Pollack AD. Homocystinuria. Studies of 20 families with 38 affected members. JAMA. 1965;193:711-719.
2. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
3. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99:178-182.
4. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
5. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc. 2005;80:219-230.
6. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
7. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
8. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
9. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:292-299.
10. Lange H, Suryapranata H, De LG, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681.
11. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
12. den Heijer M, Willems H, Blom H, Gerrits W, Cattaneo M, Eichinger S, Rosendaal F, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep-vein thrombosis and pulmonary embolism. A randomised, placebo-controlled, double-blind trial. Blood. 2007;109:139-144.
13. Wang G, Woo CWH, Sung FL, Siow YL, O K. Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol. 2002;22:1777-1783.
14. Chao CL, Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 2000;101:485-490.
15. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Tolliet M, Heyrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000;106:483-491.
16. Jiang X, Yang F, Tan H, Liao D, Bryan RM, Randhawa JK, Rumbaut RE, Durante W, Schafer AI, Yang X, Wang H. Hyperhomocysteinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol. 2005;25:2515-2521.
17. Dayal S, Arning E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke. 2004;35:1957-1962.
18. Rodriguez-Nieto S, Chavarria T, Martinez-Poveda B, Sanchez-Jimenez F, Rodriguez Quesada A, Medina MA. Anti-angiogenic effects of homocysteine on cultured endothelial cells. Biochem Biophys Res Commun. 2002;293:497-500.
19. Duan J, Murohara T, Ikeda H, Sasaki K, Shintani S, Akita T, Shimada T, Imaizumi T. Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2000;20:2579-2585.
20. Shastry S, Tyagi N, Hayden MR, Tyagi SC. Proteomic analysis of homocysteine inhibition of microvascular endothelial cell angiogenesis. Cell Mol Biol. 2004;50:931-937.
21. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase deficient mice. Circ Res. 2001;88:1203-1209.
22. Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, Lee ME. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 1997;272:25380-25385.
23. Clarke S. Protein methylation. Curr Opin Cell Biol. 1993;5:977-983.
24. Cedar H. DNA methylation and gene activity. Cell. 1988;53:3-4.
25. Lee ME, Wang H. Homocysteine and hypomethylation: a novel link to vascular disease. Trends Cardiovasc Med. 1999;9:49-54.
26. Wang H, Jiang X, Yang F, Chapman GB, Durante W, Sibinga NE, Schafer AI. Cyclin A transcriptional suppression is the major mechanism mediating homocysteine-induced endothelial cell growth inhibition. Blood. 2002;99:939-945.
27. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry PD, Yang CY. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003;107:2102-2108.
28. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Liao WSL, Yang CY, Chen CH. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting FGF2 autoregulation. Diabetes. 2008;57:158-166.
29. Chen CH, Cartwright J Jr, Li Z, Lou S, Nguyen HH, Gotto AM Jr, Henry PD. Inhibitory effects of hypercholesterolemia and oxidized LDL on angiogenesis-like endothelial growth in rabbit aortic explants: essential role of basic fibroblast growth factor. Arterioscler Thromb Vasc Biol. 1997;17:1303-1312.
30. Chen CH, Jiang W, Via DP, Luo S, Li TR, Lee YT, Henry PD. Oxidized low-density lipoprotein inhibits endothelial cell growth by suppressing basic fibroblast growth factor expression. Circulation. 2000;101:171-177.
31. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, Chen CH. Oxidized low-density lipoprotein down-regulates endothelial bFGF through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation. 2001;104:588-593.
32. Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116-2122.
33. Nakano E, Taiwo FA, Nugent D, Griffiths HR, Aldred S, Paisi M, Kwok M, Bhatt P, Hill MH, Moat S, Powers HJ. Downstream effects on human low density lipoprotein of homocysteine exported from endothelial cells in an in vitro system. J Lipid Res. 2005;46:484-493.
34. Nagase M, Ando K, Nagase T, Kaname S, Sawamura T, Fujita T. Redox-sensitive regulation of LOX-1 gene expression in vascular endothelium. Biochem Biophys Res Commun. 2001;281:720-725.
35. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
36. Hermes M, Osswald H, Mattar J, Kloor D. Influence of an altered methylation potential on mRNA methylation and gene expression in HepG2 cells. Exp Cell Res. 2004;294:325-334.
37. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res. 2004;94:28-36.
38. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209-213.
39. Lentz B, Bleich S, Beutler S, Schierf B, Schwager K, Reulbach U, Kornhuber J, Bonsch D. Homocysteine regulates expression of Herp by DNA methylation involving the AARE and CREB binding sites. Exp Cell Res. 2006;312:4049-4055.
40. Devlin AM, Bottiglieri T, Domann FE, Lentz SR. Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J Biol Chem. 2005;280:25506-25511.
41. Baric I, Fumic K, Glenn B, Cuk M, Schulze A, Finkelstein JD, James SJ, Mejaski-Bosnjak V, Pazanin L, Pogribny IP, Rados M, Sarnavka V, Scukanec-Spoljar M, Allen RH, Stabler S, Uzelac L, Vugrek O, Wagner C, Zeisel S, Mudd SH. S-adenosylhomocysteine hydrolase deficiency in a human: a genetic disorder of methionine metabolism. Proc Natl Acad Sci U S A. 2004;101:4234-4239.
42. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134:573-586.
43. Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. J Biol Chem. 1996;271:29659-29665.
44. Chen CH, Walterscheid JP. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res. 2006;99:787-789.
45. Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, Resink T, Erne P, Binder BR, Leitinger N. Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res. 2006;99:900-908.
46. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science. 2003;301:94-96.
47. Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, Kitajima S. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem. 2001;276:35867-35874.
48. Suhara T, Fukuo K, Yasuda O, Tsubakimoto M, Takemura Y, Kawamoto H, Yokoi T, Mogi M, Kaimoto T, Ogihara T. Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension. 2004;43:1208-1213.